核酸擴增試驗應用於捐血者病毒檢驗之成本效益分析

Analysis of cost saving from nucleic acid amplification testing of all blood donations for viral infection in Taiwan

10.6288/TJPH.201810_37(5).107024

許鈴宜(LING-I HSU)；程仁偉(JEN-WEI CHEN)；林東燦(DONG-TSAMN LIN)；魏昇堂(SHENG-TANG WEI)；侯勝茂(SHENG-MOU HOU)

核酸放大試驗 ； NAT yield case ； 輸血感染（TTI） ； 成本 ； nucleic acid amplification test (NAT) ； NAT yield case ； transfusion-transmitted infection (TTI) ； cost

台灣公共衛生雜誌

37卷5期（2018 / 10 / 22）

527 - 538

繁體中文

目標：台灣於2013年全面施行捐血者核酸放大試驗（Nucleic acid Amplification Test, NAT）來篩檢愛滋病毒（HIV），C型肝炎病毒（HCV）及B型肝炎病毒（HBV）。本研究以NAT實施四年所避免之輸血感染數來評估常規免疫酵素法加測NAT之後，相對於只用免疫酵素法檢測可節約之成本。方法：我們以免疫酵素法檢驗血清標記陰性而NAT檢驗陽性（NAT yield case）個案數、可製成血品數、輸血族群未曾感染比例及病毒傳染力來估計可避免輸血感染數（transfusion-transmitted infection, TTI）。雖然捐血加測NAT增加血液供應成本，但加測NAT可節省支出包含TTI之醫療照護成本、道義救濟成本、訴訟成本及HIV帶原捐血者二次傳播醫療成本。我們比較兩者之間的差異來進行成本效益分析。結果：2013-2016年共檢測7,001,347人次，NAT yield case為HIV 6人，HCV 52人及HBV 1,927人。NAT檢驗及人事成本共738,534,700元。TTI估計值為HIV 16.7例、HCV 115.6例、HBV 55.2例，以及HBV潛隱性個案持續捐血至65歲造成TTI 1,032.2例，合計可避免之TTIs共1,219.7例。可節省之醫療照護成本259,075,635元，道義救濟金642,000,000元，法律訴訟97,800,000元，捐血者二次傳播醫療成本28,448,352元，合計1,027,323,987元。結論：2013-2016台灣捐供血系統全面加測NAT實際檢驗支出7.4億元，預估可避免約1,220例TTIs，預估可節省支出10.3億元。以輸血感染事件而言，自全面篩檢至今（2018年3月）未曾發生HIV TTI，篩檢成效明確。

Objectives: Nucleic acid amplification testing (NAT) of all blood donations for human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) has been performed in Taiwan since 2013. We analyzed the benefits of universal NAT by estimating the number of prevented transfusion-transmitted infections (TTIs) and calculating the saved cost of medical expenditures, relief payments, litigation costs, and medical care for secondary HIV transmission. Methods: We determined the number of NAT yield cases (seronegative NAT-reactive donors) during the study period of 2013–2016. The number of prevented TTIs was estimated based on the number of NAT yield cases after considering the number of blood components produced per donation, recipient susceptibility, and viral infectivity. Results: Among 7,001,347 donations, we identified 6 HIV, 52 HCV, and 1927 HBV seronegative NAT-reactive donors. The expected number of prevented TTIs was 16.7 for HIV, 115.6 for HCV, and 55.2 for HBV. After further considering donations contributed from donors with occult HBV infection, an additional 1032.2 cases of TTIs were prevented. An estimated 1219.7 cases of TTIs were prevented. The cost of NAT during the 4 years was NT$740 million. The estimated savings from medical expenditures, relief payments, litigation costs, and secondary transmissions of HIV from NAT yield cases were respectively NT$259 million; NT$642 million; NT$98 million; and NT$28 million. The savings attributed to NAT screening totaled NT$1,027 million. Conclusions: Universal NAT improves the safety of blood donation. The total cost of NAT in Taiwan was NT$740 million over 4 years. An estimated 1,220 TTIs were prevented, and approximately NT$1,027 million was saved. NAT screening of donor blood is conclusively cost effective.

1. Canada's Red Cross Guilty in HIV scandal. World Net Daily May 31, 2005.
2. (1996).A special French court has completed its investigation.AABB Weekly Report,August 30
3. Japanese arrest doctor in HIV-tainted blood scandal. The New York Times August 30, 1996.
4. (1995).Japanese government apologizes to hemophilia patients with AIDS.CCBC Newsletter,October 13
5. Aldhous, P,Tastemain, C(1992).Three physicians convicted in "French blood supply" trial.Science,258,735.
6. AuBuchon, JP,Birkmeyer, JD,Busch, MP(1997).Safety of the blood supply in the United States: opportunities and controversies.Ann Intern Med,127,904-9.
7. Borkent-Raven, BA,Janssen, MP,van der Poel, CL,de Wit, GA,Bonsel, GJ,van Hout, BA(2009).Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands.Transfusion,49,311-9.
8. Borkent-Raven, BA,Janssen, MP,vander Poel, CL,Bonsel, GJ,van Hout, BA(2012).Cost-effectiveness of additional blood screening tests in the Netherlands.Transfusion,52,478-88.
9. Breo, DL(1991).Blood, money and hemophiliacs: the fatal story of France's "AIDSgate".JAMA,266,3477-82.
10. Candotti, D,Allain, JP(2009).Transfusion-transmitted hepatitis B virus infection.J Hepatol,51,798-809.
11. Cardoso, MS,Koerner, K,Hinz, W(1999).Experiences in HCV-NAT screening prior to releasing cellular components by the German Red Cross Blood Transfusion Service of Baden-Wurttemberg.Biologicals,27,281-4.
12. Davidson, T,Ekermo, B,Gaines, H,Lesko, B,Akerlind, B(2011).The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden.Transfusion,51,421-9.
13. Fang, CT,Chang, YY,Hsu, HM(2007).Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan.J Formos Med Assoc,106,631-40.
14. Fung, MK(ed.),Brenda, J(ed.),Grossman, BJ(ed.),Hillyer, CD(ed.),Westhoff, CM(ed.)(2014).Technical Manual.Bethesda, MD:American Association of Blood Banks.
15. Hepatitis C Online. Cost and access to direct-acting antiviral agents. Available at: https://www.hepatitisc.uw.edu/pdf/evaluation-treatment/cost-access-medications/core-concept/all. Accessed March 23, 2018.
16. Hill, A,Khoo, S,Fortunak, J,Simmons, B,Ford, N(2014).Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.Clin Infect Dis,58,928-36.
17. Jackson, BR,Busch, MP,Stramer, SL,AuBuchon, JP(2003).The cost-effectiveness of NAT for HIV, HCV and HBV in whole-blood donations.Transfusion,43,721-9.
18. Kao, JH(2016).Hepatitis C virus infection in Taiwan: past, present and future.J Formos Med Assoc,115,65-6.
19. Kleinman, SH,Lelie, N,Busch, MP(2009).Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion.Transfusion,49,2454-89.
20. Li, L,Chen, PJ,Chen, MH,Chak, KF,Lin, KS,Tsai, SJ(2008).A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.Transfusion,48,1198-206.
21. Liu, CJ,Lo, SC,Kao, JH(2006).Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan.J Hepatol,44,39-46.
22. Mafirakureva, N,Mapako, T,Khoza, S(2016).Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.Transfusion,56,3101-11.
23. Roth, WK,Busch, MP,Schuller, A(2012).International survey on NAT testing of blood transfusion: expanding implementation and yield from 1999 to 2009.Vox Sang,102,82-90.
24. Satake, M,Taira, R,Yugi, H(2007).Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.Transfusion,47,1197-205.
25. Sun, CA,Chen, HC,Lu, CF(1999).Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a national survey.J Med Virol,59,290-6.
26. US Food and Drug Administration. Procleix Ultrio Plus Assays. For In Vitro Diagnostic Use. Available at: https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm335203.htm. Accessed March 23, 2018.
27. van Hulst, M,Hubben, GA,Sagoe, KW(2009).Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands.Transfusion,49,2729-42.
28. Wang, JT,Lee, CZ,Chen, PJ,Wang, TH,Chen, DS(2002).Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers.Transfusion,42,1592-7.
29. Waters, RC,Ostermann, J,Reeves, TD(2011).A cost-effectiveness analysis of alternative HIV retesting strategies in sub-Saharan Africa.J Acquir Immune Defic Syndr,56,443-52.
30. WHO(2017).Global hepatitis report, 2017.
31. 朱懷祖：由美國政府與法院處理經血液感染愛滋病案之經驗論我國藥物責任之問題。https://www.cpc.ey.gov.tw/News_Content.aspx?n=EA50E0E8EAEB9A76&sms=D0E7C7246B38677C&s=43FB48DB324C92C0。引用2018/03/23。Chu WJ. Examining pharmaceutical drug liability in Taiwan using cases from the US government and courts that have managed HIV infection via menstrual blood of HIV patients. Available at: https://www.cpc.ey.gov.tw/News_Content.aspx?n=EA50E0E8EAEB9A76&sms=D0E7C7246B38677C&s=43FB48DB324C92C0. Accessed March 23, 2018. [In Chinese]
32. 行政院主計總處：受僱員工動向調查。https://www.dgbas.gov.tw/np.asp?ctNode=2845。引用2018/03/23。Directorate-General of Budget, Accounting and Statistics, Executive Yuan, R.O.C. (Taiwan). Survey on status and movements of employees. Available at: https://www.dgbas.gov.tw/np.asp?ctNode=284.Accessed March 23, 2018. [In Chinese]
33. 吳俊穎、楊增暐、賴惠蓁、陳榮基(2010)。醫療糾紛民事訴訟時代的來臨：台灣醫療糾紛民國91年至96年訴訟案件分析。台灣醫學，14，359-69。
34. 吳俊穎、楊增暐、賴惠蓁、陳榮基(2012)。醫療糾紛民事訴訟的損害賠償─法界學說、實務見解及實證研究。法學新論，36，13-51。
35. 李政益、吳宛真、楊祥麟、劉定萍(2015)。台灣2014年愛滋病毒感染流行病學分析。疫情報導，31，579-85。
36. 楊培銘(2016)。根除C肝，全面啟動。好心肝會刊，74
37. 劉嘉玲、張秀芳、黃志傑、周玉民(2016)。台灣B型肝炎防治。疫情報導，32，290-300。
38. 衛生福利部中央健康保險署：藥品給付規定\藥品給付規定內容，第十節抗微生物劑。https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC7D09599D25979。引用2018/03/23。National Health Insurance Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). National Health Insurance Drug Payment Standards. Chapter 10: antimicrobial agents. Available at https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC7D09599D25979. Accessed March 23, 2018. [In Chinese].
39. 衛生福利部疾病管制署(2013)。愛滋病檢驗及治療指引。台北=Taipei:衛生福利部疾病管制署=Centers for Disease Control, Ministry of Health and Welfare, R.O.C. (Taiwan)。
40. 賴明陽、高嘉宏(2006)。,台北=Taipei:衛生福利部疾病管制署=Centers for Disease Control, Ministry of Health and Welfare, R.O.C. (Taiwan)。